Searched for
SENORES PHARMA SHARE LISTING
Year 2008. Elon Musk was almost broke, facing divorce, close to a nervous breakdown. How just 3 days around Christmas changed his life and SpaceX fortunes foreverIn 2008, Elon Musk faced near financial ruin with SpaceX and Tesla on the brink of collapse. After a critical SpaceX launch succeeded, NASA...- World's first trillionaire: SpaceX premium debut briefly hands Elon Musk historic statusElon Musk briefly touched a trillion-dollar net worth as SpaceX shares surged on its Wall Street debut, though his wealth later settled bel...
- SpaceX shares open at $150 in Nasdaq debutSpaceX shares indicated to open at $150 in Nasdaq debut vs IPO price of $135 per share.
- GenXAI Analytics shares list at 20% discount to IPO price on NSE SME platformGenXAI Analytics shares listed on the NSE SME platform at a significant discount. The stock opened at Rs 92.8, below its IPO price of Rs 11...
- PL Capital cuts Nifty target to 26,449, lists 16 high conviction stock picksAmidst global market turmoil from the Iran-US war and El Nino, PL Capital lowered its Nifty 50 target to 26,449. The brokerage anticipates ...
- Quant Small Cap Fund raises stake in Adani Enterprises and 8 others, trims in Aurobindo Pharma and 4 moreQuant Small Cap Fund increased exposure to Adani Enterprises and eight other stocks in May while reducing holdings in Aurobindo Pharma and ...
- Two Trades for Today: 2 pharma companies – a large-cap for a 5% rise, and a mid-cap stock for a gain of 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Hexagon Nutrition shares list at 7% premium over IPO price on boursesHexagon Nutrition debuted at a premium of up to 7.2% over its IPO price, in line with grey market expectations. The Rs 138.9 crore issue wa...
- 'Time to cherry pick again': Porinju Veliyath says small and midcaps have bottomed & Thomas Cook is his latest buyPorinju Veliyath sees the correction in small and midcap stocks ending. He believes patient investors will find rewards. Thomas Cook India ...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- UHM Vacation shares list at 25% discount to IPO price on BSE SME platformUHM Vacation Listing: UHM Vacation shares debuted on the BSE SME platform at a significant 25% discount to its IPO price, listing at Rs 132...
- Vahh Chemicals shares list at 17% premium over IPO price on BSE SME platformVahh Chemicals Listing: Vahh Chemicals debuted on the BSE SME platform with a nearly 17% premium, listing at Rs 70 against its IPO price of...
- SpaceX IPO: Listing date, valuation among 10 things to know about the biggest stock market debut everElon Musk’s SpaceX is poised for a historic IPO, aiming to raise $75 billion at a $1.75 trillion valuation. Investor demand is strong, with...
- Hetero partners with Richter to develop, market Semaglutide injection globallyHyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...
- How Sensex, Nifty rallied 200% under PM Modi's record-breaking tenureIndian equity markets delivered strong long-term returns during Prime Minister Narendra Modi’s tenure, with the Sensex and Nifty gaining ar...
- CMR Green Tech shares fall 8% after solid 43% stock market debut. Buy, sell or hold?CMR Green Technologies shares fell sharply from their post-listing highs after debuting at a 43% premium to the IPO price. While analysts r...
- Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, VedantaIndian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...
- PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- SBI in $1 billion funding for Sun Pharma’s US dealState Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....
Load More
